True Synergism
Executive Summary
Schein’s $240 million acquisition of Marsam reflects the type of one-stop shopping and product breadth drug companies envisioned by drug companies when they went prospecting for generic businesses.
You may also be interested in...
GSK Aims To Launch 13 Blockbusters In Five Years
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
Need a specific report? 1000+ reports available
Buy Reports